logo-loader
viewHemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals PLC advisory board member recognised for breast cancer breakthrough

H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been acknowledged with the 2019 Lasker-DeBakey Clinical Medical Research Award

HemoGenyx Pharmaceuticals -
The Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life”

A member of HemoGenyx Pharmaceuticals PLC’s (LON:HEMO) scientific advisory board has received the American scientific equivalent to the Nobel Prize.

H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been recognised with the 2019 Lasker-DeBakey Clinical Medical Research Award.

The Lasker Foundation said that Shepard's research "executed a new blueprint for drug discovery that has already bestowed tens of thousands of women with time and quality of life”.

Hemogenyx chief executive Vladislav Sandler said: "We are thrilled that Dr Shepard's life-saving work has been recognised by this prestigious award and we are fortunate to have such a distinguished scientist advising our own organisation's cutting-edge cancer research."

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.015 GBX

LSE:HEMO
Market: LSE
Market Cap: £26.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read